AACR 2025 – Boehringer still has broad zongertinib hopes
Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.
A second shot at PARP1 from Eikon
The private US biotech features among recent first-in-human study entrants, with another PARP1-selective molecule.
Oric looks over its shoulder
Tough equity markets as well as competitor developments prompt a narrowed focus.
Boehringer beats Bayer to the regulators
The FDA will rule on a low dose of zongertinib in the summer.
Novartis’s post-Pluvicto plan materialises
The company has two actinium-labelled PSMA radiopharmaceuticals, and one is about to pivotal.
Atara still can't get across the US finish line
Just when investors thought things couldn't get any worse, they do.
Targeted lung cancer niche sees a German pharma battle
But could toxicity be holding back filing plans?
No SOS for Bayer's SOS1
The group goes after a KRAS-related target on which Boehringer recently gave up.
World Lung 2024 – Boehringer and Bayer battle over a lung cancer niche
Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.
